Lipid-lowering Therapy Individualization

Status Completed

Clinical Trial Summary

This clinical study will explore individual factors influencing statin pharmacokinetics in a cohort of 150 patients treated with atorvastatin.

Clinical Trial Description

Atorvastatin is widely prescribed for the treatment of hypercholesterolemia to prevent the risk of cardiovascular diseases, a leading death cause in industrialized countries. There exists considerable inter-individual variability in response to statins, reflected by differences in lipid-lowering effect or risk of presenting adverse drug reaction; mainly myotoxicity. A plethora of different factors (demographic, genetic, physiopathologic, environmental...) have been tested to explain this variability but it lacks of pharmacokinetic (PK) data and/or replications of observations are rare and results remain inconclusive, probably because of non-adapted designs and no-clear driven-hypothesis but also due to a lack of scientific rationale and deep mechanistic understanding. This clinical study will explore individual factors influencing statin PK in a cohort of 150 patients treated with atorvastatin. The collection of meticulous clinical PK data and a rigorous statistical analysis will allow quantifying the effect of each identified parameter on statin PK and eventually, defining a population-based PK model taking into account the combined effect of all covariates in a quantitative approach. This innovative prospectively designed clinical study will ultimately allow predicting atorvastatin PK fluctuations and anticipating any inadequate dosing in clinical care. ;

Study Design

Related Conditions & MeSH terms

Hypercholesterolemia

Clinical Trial Details

NCT number	NCT03604471
Study type	Interventional
Source	Université Catholique de Louvain
Contact
Status	Completed
Phase	Phase 4
Start date	August 8, 2017
Completion date	August 27, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04998695` - Health Effects of Consuming Olive Pomace Oil	N/A
Recruiting	`NCT03947866` - Ezetimibe-Rosuvastatin Evaluation Study
Completed	`NCT01709513` - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)	Phase 3
Completed	`NCT01212900` - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression	Phase 4
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed	`NCT02550288` - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Phase 3
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT04485793` - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia	N/A
Completed	`NCT02341924` - Validating the "Foods for Health" Portfolio of Functional Food Products	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Completed	`NCT01941836` - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients	Phase 2
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01678521` - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients	N/A
Completed	`NCT01670734` - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects	Phase 1
Completed	`NCT01370603` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)	Phase 3
Completed	`NCT01370590` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)	Phase 3
Completed	`NCT01575171` - Using Nudges to Implement Comparative Effectiveness	N/A
Completed	`NCT01446679` - Special Drug Use-Results Survey of Lipitor Tablets	N/A
Completed	`NCT01768403` - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia	N/A